全文获取类型
收费全文 | 42159篇 |
免费 | 3455篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 560篇 |
儿科学 | 1355篇 |
妇产科学 | 968篇 |
基础医学 | 5612篇 |
口腔科学 | 754篇 |
临床医学 | 6108篇 |
内科学 | 7389篇 |
皮肤病学 | 623篇 |
神经病学 | 3436篇 |
特种医学 | 997篇 |
外科学 | 5042篇 |
综合类 | 685篇 |
一般理论 | 60篇 |
预防医学 | 5116篇 |
眼科学 | 850篇 |
药学 | 2714篇 |
2篇 | |
中国医学 | 23篇 |
肿瘤学 | 3392篇 |
出版年
2023年 | 221篇 |
2022年 | 305篇 |
2021年 | 717篇 |
2020年 | 451篇 |
2019年 | 689篇 |
2018年 | 856篇 |
2017年 | 690篇 |
2016年 | 740篇 |
2015年 | 818篇 |
2014年 | 1123篇 |
2013年 | 1680篇 |
2012年 | 2508篇 |
2011年 | 2483篇 |
2010年 | 1378篇 |
2009年 | 1243篇 |
2008年 | 2247篇 |
2007年 | 2482篇 |
2006年 | 2406篇 |
2005年 | 2337篇 |
2004年 | 2201篇 |
2003年 | 2094篇 |
2002年 | 1929篇 |
2001年 | 903篇 |
2000年 | 851篇 |
1999年 | 803篇 |
1998年 | 491篇 |
1997年 | 423篇 |
1996年 | 418篇 |
1995年 | 365篇 |
1994年 | 377篇 |
1993年 | 314篇 |
1992年 | 654篇 |
1991年 | 584篇 |
1990年 | 554篇 |
1989年 | 559篇 |
1988年 | 510篇 |
1987年 | 481篇 |
1986年 | 461篇 |
1985年 | 438篇 |
1984年 | 375篇 |
1983年 | 294篇 |
1982年 | 263篇 |
1981年 | 279篇 |
1980年 | 214篇 |
1979年 | 321篇 |
1978年 | 292篇 |
1977年 | 203篇 |
1974年 | 271篇 |
1973年 | 213篇 |
1972年 | 211篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant 总被引:8,自引:0,他引:8
Barkan AL Burman P Clemmons DR Drake WM Gagel RF Harris PE Trainer PJ van der Lely AJ Vance ML 《The Journal of clinical endocrinology and metabolism》2005,90(10):5684-5691
CONTEXT: In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose homeostasis and safety has not been reported. OBJECTIVES: The objectives of this study were to monitor changes in IGF-I levels, glycemic control, and safety, particularly liver function and tumor size. DESIGN: This was a multicenter, open-label, 32-wk trial study. SETTING: The study was performed at outpatient clinics. PATIENTS: Fifty-three patients with acromegaly previously treated with octreotide long-acting release (LAR) participated in this study. Intervention: Pegvisomant (10 mg/d) was initiated 4 wk after the last dose of octreotide LAR and was adjusted based on serum IGF-I concentrations at wk 12, 20, and 28. MAIN OUTCOME MEASURES: The main outcome measures were changes in IGF-I, glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose, and safety during the first 12 wk after conversion. RESULTS: At the end of pegvisomant treatment, IGF-I was normalized in 78% of patients. At wk 32, median fasting glucose concentration and HbA1c were reduced (-1.4 mmol/liter and -0.4%, respectively; both P < or = 0.0001) in the study population. Improvements in glycemic control occurred in patients with normal IGF-I concentrations at wk 4 [n = 15; fasting glucose, -1.7 mmol/liter (P < or = 0.0001); HbA1c -0.2% (P = 0.03)]. Decreases in fasting glucose and HbA1c levels were observed in patients with and without diabetes. HbA1c was reduced by more than 1.0% in patients with diabetes. Median pituitary tumor volume did not change, although tumor volume increased in two patients with macroadenomas. CONCLUSIONS: Conversion from octreotide LAR to pegvisomant was safe and well tolerated. Improved glycemic control indicates that pegvisomant should be considered in patients with acromegaly and diabetes. 相似文献
992.
Colbert LH Visser M Simonsick EM Tracy RP Newman AB Kritchevsky SB Pahor M Taaffe DR Brach J Rubin S Harris TB 《Journal of the American Geriatrics Society》2004,52(7):1098-1104
OBJECTIVES: To examine the association between physical activity and inflammatory markers, with consideration for body fatness and antioxidant use. DESIGN: Cross-sectional study, using baseline data from the Health, Aging and Body Composition Study. SETTING: Metropolitan areas surrounding Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Black and white, well-functioning men and women (N=3,075), aged 70 to 79. MEASUREMENTS: Interviewer-administered questionnaires of previous-week household, walking, exercise, and occupational/volunteer physical activities. Analysis of covariance was used to examine the association between activity level and serum C-reactive protein (CRP), interleukin-6 (IL-6), and plasma tumor necrosis factor alpha (TNFalpha) with covariate adjustment. Antioxidant supplement use (multivitamin, vitamins E or C, beta carotene) was evaluated as an effect modifier of the association. RESULTS: Higher levels of exercise were associated with lower levels of CRP (P<.01), IL-6 (P<.001), and TNFalpha (P=.02) (e.g., CRP=1.95 mg/L for no exercise and 1.72 for >180 min/wk). Adjustment for body fatness attenuated the associations somewhat. Use of antioxidant supplements modified the CRP (P(interaction)=.01) and IL-6 (P(interaction)=.08) associations such that concentrations were low in those taking supplements (e.g., CRP=1.79-1.84 across exercise levels) and higher in nonsupplement users who did no exercise (2.03) than in those who did the most (1.72). Among nonexercisers, higher levels of other physical activity were related to lower levels of CRP (P<.01) and IL-6 (P=.02) but not TNFalpha (P=.36), even after accounting for body fat. CONCLUSION: Inflammatory markers are lower in older adults with higher levels of exercise and nonexercise activity and in antioxidant supplement users regardless of exercise level. 相似文献
993.
994.
995.
Stacy Schantz Wilkins PhD Rebecca J. Melrose PhD Katherine S. Hall PhD Erin Blanchard MS Steven C. Castle MD Teresa Kopp PT MBA Leslie I. Katzel MD PhD Alice Holder MHS PT Neil Alexander MD Michelle K.S. McDonald BA OT Arti Tayade MD CMD HMDC Daniel E. Forman MD Lauren M. Abbate MD PhD Rebekah Harris PT DPT PhDc Willy M. Valencia MD Miriam C. Morey PhD Cathy C. Lee MD 《Journal of the American Geriatrics Society》2021,69(4):1045-1050
996.
997.
998.
Spoorthy Kulkarni Raunak Rao James Delman Harry Goodman Kathleen Connolly Kevin M. O'Shaughnessy 《Medicine》2021,100(14)
Medication nonadherence represents a modifiable risk factor for patients with hypertension. Identification of nonadherent patients could have significant clinical and economic implications in the management of uncontrolled hypertension.We analysed the results of 174 urinary adherence screens from patients referred to Addenbrooke''s Hospital, Cambridge, for uncontrolled hypertension. Cases were identified for evaluation by results of liquid chromatography-tandem mass spectrometry of urine samples (males: 91; females: 83; age range: 17–87). We performed a binary logistic regression analysis for nonadherence using age, sex, and number of medications prescribed (both antihypertensives and non-antihypertensives separately) as independent predictors. Rates of nonadherence for individual antihypertensive drugs were calculated if prescribed to ≥10 patients.The overall rate of nonadherence to one or more prescribed antihypertensive medications was 40.3%. 14.4% of all patients were nonadherent to all prescribed antihypertensive medications (complete nonadherence), whereas 25.9% of all patients were nonadherent to at least 1, (but not all) prescribed antihypertensive medications (partial nonadherence). 72% of patients were prescribed ≥3 antihypertensives And for every increase in the number of antihypertensive medications prescribed, nonadherence increased with adjusted odds ratios of 2.9 (P < .001). Logistic regression showed that women were 3.3 times more likely to be nonadherent (P = .004). Polypharmacy (≥6 medications prescribed for hypertension and/or concomitant comorbidities) was prevalent in 52%. Bendroflumethiazide and chlortalidone demonstrated the highest and lowest nonadherences respectively (45.5% and 11.8%).Rate of nonadherence in patients with hypertension was significantly impacted by sex and number of antihypertensive medications prescribed. Understanding these factors is crucial in identifying and managing nonadherence. 相似文献
999.
1000.
Chang Joy W. Rubenstein Joel H. Mellinger Jessica L. Kodroff Ellyn Strobel Mary J. Scott Melissa Mack Denise Book Wendy Sable Kathleen Kyle Scholeigh Paliana Allisa Dellon Evan S. 《Digestive diseases and sciences》2021,66(6):1808-1817
Digestive Diseases and Sciences - Little is known about patient choice in treatment of eosinophilic esophagitis (EoE). Determine motivators and barriers to using common EoE therapies and describe... 相似文献